A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a bioc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Dvela-Levitt, Moran, Melanson, Michelle, Chamberlain, Brian T., Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Grinkevich, Elizabeth, Bricio, Estefania Reyes, Kim, Choah, Clark, Abbe, Watts, Andrew, Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Lucienne, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337390/
https://ncbi.nlm.nih.gov/pubmed/32637960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.30.180380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados